Patents Assigned to Celgene Corporation
  • 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS
    Publication number: 20200291039
    Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
    Type: Application
    Filed: June 2, 2020
    Publication date: September 17, 2020
    Applicants: Array BioPharma Inc., Celgene Corporation
    Inventors: Shelley Allen, Mark Laurence Boys, Mark J. Chicarelli, Jay Bradford Fell, John P. Fischer, John Gaudino, Erik James Hicken, Ronald Jay Hinklin, Christopher F. Kraser, Ellen Laird, John E. Robinson, Tony P. Tang, Laurence E. Burgess, Robert Andrew Rieger, Jed Pheneger, Yoshitaka Satoh, Katerina Leftheris, Raj K. Raheja, Brydon L. Bennett
  • Methods of synthesis of (1R, 2R, 5R)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
    Patent number: 10774033
    Abstract: Provided herein are methods and intermediates for making (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride, which are useful for the preparation of compounds useful for the treatment of a disease, disorder, or condition associated with the JNK pathway.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: September 15, 2020
    Assignee: Celgene Corporation
    Inventors: Terrence Joseph Connolly, Hon-Wah Man, Periyandi Nagarajan, Chinnapillai Rajendiran, Jasti Venkateswarlu
  • Methods of treating vitiligo using PD-1 binding antibodies
    Patent number: 10766958
    Abstract: Provided herein are methods for managing, treating, or preventing vitiligo using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: September 8, 2020
    Assignee: Celgene Corporation
    Inventor: Garth E. Ringheim
  • Methods of treating psoriasis using PD-1 binding antibodies
    Patent number: 10751414
    Abstract: Provided herein are methods for managing, treating, or preventing immune disorders, such as autoimmune diseases, using proteins that specifically bind to Programmed Death-1 (PD-1) and modulate the expression and/or activity of PD-1.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: August 25, 2020
    Assignee: Celgene Corporation
    Inventors: Henry H. Chan, Eun Mi Hur, Roli Khattri, Monica Leung, Garth E. Ringheim, Peter H. Schafer
  • Animal and human anti-malarial agents
    Patent number: 10736899
    Abstract: Provided herein are Purine Compounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: August 11, 2020
    Assignee: Celgene Corporation
    Inventors: Stacie S. Canan, Natalie Anne Hawryluk
  • 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors
    Patent number: 10730880
    Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: August 4, 2020
    Assignees: Array BioPharma Inc., Celgene Corporation
    Inventors: Shelley Allen, Mark Laurence Boys, Mark J. Chicarelli, Jay Bradford Fell, John P. Fischer, John Gaudino, Erik James Hicken, Ronald Jay Hinklin, Christopher F. Kraser, Ellen Laird, John E. Robinson, Tony P. Tang, Laurence E. Burgess, Robert Andrew Rieger, Jed Pheneger, Yoshitaka Satoh, Katerina Leftheris, Raj K. Raheja, Brydon L. Bennett
  • Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate
    Patent number: 10717703
    Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: July 21, 2020
    Assignee: Celgene Corporation
    Inventors: John F. Traverse, Michael J. Zacuto, Weihong Zhang, Kirsten Faye Johnson, Maryll E. Geherty, Christopher Marton
  • Combination therapy for treating malignancies
    Patent number: 10695352
    Abstract: Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: June 30, 2020
    Assignees: Celgene Corporation, Agios Pharmaceuticals, Inc.
    Inventors: Vivek Saroj Kumar Chopra, Jorge DiMartino, Laurie A. Kenvin, Robert Douglas Knight, Kyle MacBeth, Krishnan Viswanadhan, Qiang Xu, Samuel V. Agresta
  • Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
    Patent number: 10689708
    Abstract: In one aspect, provided herein are methods for predicting the responsiveness of DLBCL patients to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers that correlate with responsiveness to one of these drugs. In another aspect, provided herein are methods for treating a DLBCL patient determined to be responsive to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers (or output thereof) that correlate with responsiveness to one of these drugs.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: June 23, 2020
    Assignee: CELGENE CORPORATION
    Inventors: Matthew William Burnell Trotter, Alberto Risueno Perez, Michael Pourdehnad, Anita Gandhi, Patrick Hagner
  • Antiproliferative compounds and methods of use thereof
    Patent number: 10675281
    Abstract: Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: June 9, 2020
    Assignee: Celgene Corporation
    Inventors: Matthew D. Alexander, Gerald D. Artman, III, Matthew D. Correa, Joshua Hansen, Xiaoling Lu, Hon-Wah Man, Mark A. Nagy, Paula A. Tavares-Greco, Brandon W. Whitefield, Nanfei Zou
  • Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
    Patent number: 10668057
    Abstract: Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: June 2, 2020
    Assignee: CELGENE CORPORATION
    Inventors: Philip Chamberlain, Brian E. Cathers, Antonia Lopez-Girona
  • Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
    Patent number: 10669257
    Abstract: Provided are 4?-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: June 2, 2020
    Assignee: Celgene Corporation
    Inventors: Hon-Wah Man, Roger Shen-Chu Chen, George W. Muller, Alexander L. Ruchelman, Ehab M. Khalil, Weihong Zhang
  • Compositions and methods of use of cis-4-[2-{[3S,4R)-3-fluorooxan-4-yl]amino}8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
    Patent number: 10653697
    Abstract: Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: May 19, 2020
    Assignee: Celgene Corporation
    Inventors: Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
  • Combination therapy for treating malignancies
    Patent number: 10653710
    Abstract: Provided are methods and compositions for treating hematological malignancies in patients carrying an IDH1 mutation using a combination of an inhibitor of mutant IDH1 enzyme, (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt thereof (COMPOUND 2) and a DNA demethylating agent.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: May 19, 2020
    Assignees: Agios Pharmaceuticals, Inc., Celgene Corporation
    Inventors: Samuel V. Agresta, Krishnan Viswanadhan, Jorge DiMartino, Vivek Saroj Kumar Chopra, Kyle J. MacBeth, Robert Douglas Knight, Laurie Kenvin, Qiang Xu
  • Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
    Patent number: 10648983
    Abstract: A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is a compound of Formula I:
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: May 12, 2020
    Assignee: Celgene Corporation
    Inventors: Ellen Filvaroff, Antonia Lopez-Girona, Gang Lu
  • Isotopologues of 5-azacytidine
    Patent number: 10646503
    Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for oral administration, wherein the compositions release the cytidine analog substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: May 12, 2020
    Assignee: Celgene Corporation
    Inventors: John F. Traverse, William W. Leong, Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
  • Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
    Patent number: 10626101
    Abstract: Solid forms comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, compositions comprising the solid forms, methods of making the solid forms and methods of their uses are disclosed.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: April 21, 2020
    Assignee: Celgene Corporation
    Inventors: Ying Li, Hon-Wah Man
  • METHODS OF CLASSIFYING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20200118646
    Abstract: A method of predicting if a subject has an Activated B Cell-like (ABC) subtype or a non-ABC subtype of Diffuse Large B-Cell Lymphoma (DLBCL), comprising (a) obtaining a sample from the subject; (b) measuring the expression levels of CD10, MUM1, FOXP1, and optionally Bcl-6; (c) determining a composite score based on the expression levels of CD10, MUM1, and FOXP1, and optionally Bcl-6; and (d) predicting if the subject has an ABC subtype or a non-ABC subtype of DLBCL based on the composite score.
    Type: Application
    Filed: October 9, 2019
    Publication date: April 16, 2020
    Applicant: CELGENE CORPORATION
    Inventors: Yixin WANG, Sarah HERSEY, Fadi George TOWFIC, Alberto RISUENO PEREZ
  • Antiproliferative compounds, and their pharmaceutical compositions and uses
    Patent number: 10618883
    Abstract: Compounds of formula A-I and B-I, compositions comprising the compounds, methods of making the compounds and methods of their uses are disclosed.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: April 14, 2020
    Assignee: Celgene Corporation
    Inventors: Matthew D. Alexander, Matthew D. Correa, Joshua Hansen, Raj Kumar Raheja, John Sapienza
  • Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereof
    Patent number: 10604510
    Abstract: Provided herein are compositions including the crystalline forms of (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[b]azepine-4-carboxamide (“Compound A”), methods of making the crystalline forms, and methods of using the crystalline forms for the treatment of diseases, including, for example, cancer.
    Type: Grant
    Filed: September 13, 2019
    Date of Patent: March 31, 2020
    Assignee: Celgene Corporation
    Inventors: Hon-Wah Man, Timothy D. Fitzpatrick, Anthony Frank, Ying Li, Xiaoling Lu, Marie G. Beauchamps, Antonio C. Ferretti